M&A / Deals Teva and Polpharma Biologics sign global deal for ocrelizumab biosimilar pharminent July 10, 2026
M&A / Deals AstraZeneca bets up to $1.9B in respiratory disease collab with Sino Biopharmaceutical pharminent July 8, 2026
M&A / Deals Ipsen to buy Swiss biotech Memo Therapeutics in potential $800M deal pharminent July 1, 2026
M&A / Deals Ionis grants Recordati rights to zilganersen for Alexander disease pharminent June 26, 2026
M&A / Deals URA and Lilly join forces to harmonise drug-wearable obesity care pharminent June 24, 2026
M&A / Deals LG AI Research and D&D Pharmatech sign agreement for oral peptide drugs pharminent June 18, 2026
M&A / Deals Merck adds to biopharma’s AI agenda with up to $510M+ Protillion pact pharminent June 17, 2026
M&A / Deals Sky-high Parabilis, Kailera IPOs spur optimism–but only for derisked biotechs pharminent June 11, 2026
M&A / Deals Beren pockets $300m to take Niemann-Pick disease therapy to market pharminent June 11, 2026
M&A / Deals Alzecure enters collaboration and with Lilly for Alzheimer’s project pharminent June 9, 2026
M&A / Deals GSK pays $10.6B for cancer biotech Nuvalent in industry’s second-biggest buy of the year pharminent June 9, 2026
M&A / Deals J&J to acquire Firefly, maker of ‘degrader’ antibody drugs, for up to $1B pharminent June 8, 2026
